Policy & Regulation
Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X Platform and CorPlex Validated 10-Plex
11 January 2019 - - US-based Quanterix Corp. (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, has launched of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels, the company said.

According to the company, this new instrument platform and highly validated CorPlex assays promise to revolutionize oncology research and drug development.

The progress made since the early access program was initiated in early November 2018 with select industry leaders has validated the performance and promise of the technology, resulting in an accelerated timeline for full launch.

Quanterix is now taking orders for shipping by April 1.

For the first time, researchers are able to access over one thousand assay configurations of critical immunomodulatory biomarkers for oncology research with multiplexing up to 10-plex without sacrificing sensitivity.

The broad assay menu covers more than 50 analytes and enables researchers to easily develop custom homebrew assays, further extending the range of applications to include PK/PD and immunogenicity assays as well.

Simoa CorPlex assays undergo extensive validation, providing one of the most highly validated assay menus in the industry, ensuring customers can utilise the assays in the most demanding clinical and translational research applications.

The next generation Simoa planar array technology utilized in CorPlex assays promotes non-invasive biomarker measurements, supporting easier and more approachable methods for determining drug efficacy and toxicity.

This addresses the previously unmet needs of oncology researchers, particularly in the rapidly expanding fields of immuno-oncology and immunotherapy, including checkpoint inhibitors and CAR-T cell therapies.

While immunotherapies have gained traction as a promising way to treat many cancers, the inability to optimise dosing and the occurrence of immune-related adverse events have hindered progress.

Critical biomarkers that would enable researchers to make informed decisions with respect to dosing and toxicities are often at such low concentrations that the reliable measurement has been problematic until now.

With Simoa CorPlex assays, researchers can measure concentrations of key circulating cytokines and immunological biomarkers across all stages of disease progression including normal healthy baseline levels.

This means that researchers will be able to more quickly see whether the immunotherapy or other cancer treatments are working, or potentially avoid severe side effects such as neurotoxicity and cytokine release syndrome.

This means the Simoa CorPlex could have the potential to catalyze dramatic reductions in treatments costs, which can amount to several hundred thousand dollars a year.

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health.

The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided TODAY by giving researchers the ability to closely examine the continuum from health to disease.

Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.
Login
Username:

Password:


Related Headlines